NEW YORK, July 26, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Nanobiotechnology Industryhttp://www.reportlinker.com/p0181059/Global-Nanobiotechnology-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Nanotechn
This report analyzes the worldwide markets for Nanobiotechnology in US$ Million by the following Technology Segments: Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, & Other Nanomaterials), and Nanodevices/Tools. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 117 companies including many key and niche players worldwide such as Aduro BioTech, Arrowhead Research Corporation, Calando Pharmaceuticals, Inc., Agilent Technologies Inc., Asklepios BioPharmaceutical Inc., Biosante Phosphate Pharmaceuticals, Inc., Celgene Corporation, Elan Pharmaceuticals, Elitech Group, Flamel Technologies, Inc., Gilead Sciences Inc., Life Technologies Corporation, NanoBio Corporation, Nanogen, Inc., Nanophase Technologies Corporation, pSivida Ltd., Sigma Aldrich Company, Starpharma Holdings Ltd., Dendritic Nanotechnologies, Inc., SkyePharma Pharmaceuticals, Unidym, Inc., and Zyvex Instruments LLC. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-3Quantitative Techniques & Analytics I-3Product Definitions and Scope of Study I-31. Nanomaterials I-4Solid Inorganic Nanoparticles I-4Nanocomposites I-4Nanostructured Materials and Membranes I-4Nanotubes and Fullerenes I-4Other Nanomaterials I-4Nanoshells I-4Nanohorns I-5Nanocapsules I-52. Nanodevices/Tools I-5II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW II-1
A Curtain Raiser II-1
Nanobiotechnology - The Next Big Thing II-2
Nanotechnology & Biology Tie the Knot: "Two to Tango" II-4
Where Conventional Molecular Science Falls Short Nanobio
Steps In II-4
What's The Obsession With Size? II-5
Why Analysis at the Cellular Level is Important? II-5
Lessons from Nature II-6
Dawn Breaks On Nanobiotechnology II-6
Table 1: Nanobiotechnology and Related Medical Applications
Market (2007): Percentage Share Breakdown of Activity
Distribution by Region and Organizational Set-Up (includes
corresponding Graph/Chart) II-7
Table 2: Percentage Breakdown of Number of NanotechnologyCompanies in Healthcare Industry Worldwide by Region/Country(2008) (includes corresponding Graph/Chart) II-7
Table 3: Percentage Breakdown of Number of Nanotechnology
Companies in Healthcare Industry Worldwide by Type - Private
and Public Sector (2008) (includes corresponding Graph/Chart) II-7
Table 4: Percentage Breakdown of Number of NanotechnologyCompanies in Healthcare Industry Worldwide By Sector -Therapeutics and Drug Delivery; Clinical Diagnostics; DrugDiscovery Tools and Biomedical Research; and Biomaterials andBiomedical Implants (2008) (includes correspondingGraph/Chart) II-8
Table 5: Percentage Breakdown of Number of Nanotechnology
Companies in The field of Therapeutics and Drug Delivery
Worldwide by Area - Targeted Nanoparticles, Solubility &
Reformulation, Sustained Release, Blood Brain Barrier,
Nanomaterial Therapeutics and Others (2008) (includes
corresponding Graph/Chart) II-8
Table 6: Percentage Breakdown of Number of NanotechnologyCompanies in the field Therapeutics Worldwide by TherapeuticArea - Oncology, Infectious Diseases, Central Nervous SystemDiseases, Nutraceuticals, Ophthalmology and Others (2008)(includes corresponding Graph/Chart) II-9
Table 7: Percentage Breakdown of Number of Nanotechnology
Companies in the field of Clinical Imaging and Diagnostics
Worldwide by Area - Tags and Probes; Imaging Agents;
Biosensors and Bio-detection; and Instruments (2008)
(includes corresponding Graph/Chart) II-9
Demystifying the Intriguing World of Nanobiotech II-9
A Meeting Place of Medicine's Best Solutions II-10
Nanobiotechnology Promises to Deliver Nanomedicine II-11
Nanobiotechnology to Become Viable for All Drug Development
Stages II-12
Nanobioproducts in R&D As of 2007 & 2008 II-13
List of Marketed Nanoparticle-Based Pharmaceutical Products
As of the Year 2007 II-13
Nanoparticles: The Foundation of Nanobiotechnology II-14
Improved Optical Properties and Stability of Nanoparticles II-14
Nanoemulsions II-15
Diagnosis & Treatment of Cancer II-15
The Promise of Nanobiotechnology II-16
Biological Weaponries Against Diseases Come in Small Packages II-16
Proffered Benefits of Nanobiotechnology II-17
Opportunity & Beyond II-17
Nanobiotechnology - Will it Live Up to the Expectations? II-18
The Future of Nanobiotechnology: Shape of Things to Come II-18
Nanobiotechnology: The Outer Limits II-18
Futuristics: A Rumination II-19
Nanobiotechnology In the Year 2015 II-20
Field of Nanodiagnostics II-20
Field of Regenerative Medicine II-20
Field of Targeted Drug Delivery II-20
Conclusions II-20
2. MARKET DYNAMICS II-21Nanotechnology & the 2007-2009 Recession: A Review II-21Nanobio Feels the Pinch or Does It ? : A Closer Look II-21Will Growth in Europe Be Held Hostage by the Debt Crisis? II-22Outlook II-22Developing Countries to Rise Over the Horizon II-22Table 8: Global Nanobiotechnology Market (2009): PercentageShare Breakdown of Investments by Region (includescorresponding Graph/Chart) II-23
Table 9: Worldwide Funding in Nanotechnology (2005 & 2010):
Percentage Breakdown of Value Investments by Region/Country:
A Comparison (includes corresponding Graph/Chart) II-23
Nanomaterials & Nanoparticles Witness Robust Activity II-24
Focus on Improved Performance to Bring New Manufacturing
Methods for Nanomaterials II-24
Private & Public Companies to Step Up Funding on Nanotechnology II-24
Table 10: Worldwide Government Funding in Nanotechnology
(2008-2015) (In US$ Billion) (includes corresponding
Graph/Chart) II-25
Increasing Awareness on Technology to Drive Growth II-25
Demand for Novel Products to Push Up Growth II-26
Nano-Enabled Drug Discovery Holds Tremendous Potential II-26
Consolidation Sharpens the Industry's Edge II-26
The Regulatory Framework Evolves with the Technology II-26
Quantum Dot Patents Pose Legal Tangles II-27
Miniaturized Liquid Handling Becomes Progressive II-27
Trends in Nanotechnology Enabled Drug Delivery Systems II-28
Robust Growth On Cards II-28
Table 11: Global Nanotechnology-Enabled Drug Delivery
Systems Market (2015 (P)): Percentage Share Breakdown of
Nanoparticles, Dendrimers, Polymer Therapeutics and Other
Nanostructures (includes corresponding Graph/Chart) II-28
Patent Expiries: A Key Driver II-29
Nanotechnology Enabled Drug Delivery to Exhume Unused Drugs II-29
3. INDUSTRY CHALLENGES & ISSUES II-30Challenges II-30Commercial Exploration: A Treacherous Voyage II-31Conventional Medicine to Contest Nanomedicine Adoption II-31Nanomaterials Use: Weighed Down with Toxicity Concerns II-32Production Issues Continue to Plague Nanobiotech Industry II-33Lack of De Facto Standards: A Challenge to Reckon With II-33Embroilment Over Ethical Issues II-34Social Relevance II-35Economic Relevance II-36
4. INDUSTRY STRUCTURE II-37
Industry Structure: A Quick Primer II-37
A Dissection of Select Segments II-37
Nanoparticles II-37
Nanotubes and Fullerenes II-38
Dendrimers II-38
A Peek Into the Regulatory Framework II-38
United States II-39
Europe II-39
A Closer Look at Regional Nano Efforts II-39
United States: Unraveling the Country's Edge II-39
Table 12: Global Intellectual Property Rights in
Nanotechnology by Leading Countries (2007) (includes
corresponding Graph/Chart) II-40
Europe: Hot On the Heels of the US II-40
Germany II-41
France II-41
United Kingdom II-41
Scandinavia II-41
Japan: A Noteworthy Region II-42
5. NANOBIO'S EPOCHAL STRIDES IN MODERN MEDICINE II-43A Primer II-43Impact on Drug Delivery Systems II-43Benefits Offered II-45Drug Encapsulation II-45High Level of Specificity II-45Increase in Drug Solubility and Uptake II-45Greater Usage Flexibility II-46Impact On Molecular Diagnostic Imaging II-46Seeing The Unseen II-46Impact On Pharmaceutical Drug Formulations II-47Impact On Therapeutics II-48Silver Nanoparticles as Effective Antimicrobial Agents II-48Modern Day Nanomedicine: A Current Scenario II-49Nanomedicine: The Cynosure of All Eyes II-49Drug Delivery Systems Epitomized by Nanomedicine II-50Targeted NanoDrug Delivery & Release II-50Active and Passive Targeting Mechanisms in Drug Delivery II-51Sustained and Pulsatile Release Mechanisms in Drug Delivery II-51A Peek Into Potential Nanobio Enabled Drug Carriers II-51Micelles II-52Liposomes II-52Dendrimers & Liquid Crystals II-52Nanoparticles II-52Polymeric Nanoparticles II-53Hydrogels II-53Molecularly Imprinted Polymers II-53Microelectromechanical Systems (MEMS) II-53Nanosuspensions II-54Fullerenes: A Platform for GenX Drug Delivery II-54Types of Nano-Based Drug Delivery Systems, RelatedMaterials, and Structures II-55Dynamics of Regenerative Medicine II-55Tissue Engineering and Restorations II-56Nanotechnology Enabled Diagnostics II-57Promised Path Breaking Applications in Molecular Diagnostics& Imaging II-57In-Vitro Diagnostics II-58Nanoprobes & Implantable Devices in In-vivo Imaging II-59Nanocomposites in Molecular Labeling & Diagnostics II-60Laboratory-on-a-Chip - A Revolutionary Technology inBiomolecular Detection II-60Biosensors - Heralding New Opportunities in MolecularDiagnostics II-61Nanobiosensors - A New Approach to Diagnostics Testing II-61Despite Huge Potential Key Hurdles Remain inCommercialization II-62Magnetic Nanoparticles for Imaging Applications in MRI II-62Dendrimers Promise Milestone Applications in MRI II-62Conclusions II-63Gauging the Real World Impact of Nanobiotech On Cancer: A CaseStudy II-63Quantum Dots Cock a Snook at Traditional Anti-Body LabelingAgents II-64Chemotherapeutic Reengineering & Gene Therapy: New TreatmentRegimes II-64Laboratory-on-chip (LOC): A Platform for Cancer Diagnosis II-65
6. CONCEPTUAL OVERVIEW II-66
Nanotechnology: An Introduction II-66
A Revolution in the Making II-66
Nanobiotechnology: An Exposition II-67
Nanobiotechnology & Medicine II-67
Nanobiotechnology & Biofuels II-68
Global Nanobiotechnology Market (2005): Major Products II-68
Global Nanobiotechnology Market (2005): Major Products Under
Development II-69
Analysis of Major Technology Segments II-69
Nanomaterials II-69
Nanoparticles II-70
Nanoparticles in Labeling or Bio Tagging II-70
Nanoparticles as Biomarkers II-71
Classification of Nanoparticles II-71
Solid Nanoparticles II-71
Solid Lipid Nanoparticles II-71
Calcium Phosphate Nanoparticles II-71
Dendrimers II-72
Nanocomposites II-72
Lamellar Nanocomposites II-73
Nanostructured Materials and Membranes II-73
Nanotubes and Fullerenes II-73
Other Nanomaterials II-74
Nanoshells II-74
Nanohorns II-74
Nanocapsules II-74
Nanodevices II-75
Nanotools II-75
Select Nanotools II-75
Atomic Force Microscopes II-75
Hot Embossing Lithography II-76
Dip-Pen Nanolithography II-76
7. GLOBAL RESEARCH CENTERS AND INSTITUTIONS II-77Centre for Biologic Nanotechnology (USA) II-77Centre for Biological and Environmental Nanotechnology (USA) II-77Institute of Bioengineering and Nanotechnology (Singapore) II-77The Nanobiotechnology Center (USA) II-78The Tyndall National Institute (Ireland) II-78
8. STRATEGIC CORPORATE DEVELOPMENTS II-79
Agilent Acquires BIOCIUS II-79
IDEX Inks Deal to Acquire Microfluidics II-79
NanoMech Takes Over Canano II-79
Arrowhead Sells Unidym to Wisepower II-80
MP Biomedicals Signs Agreement of Cooperation with Russian
Nanotechnology Corporation II-80
Bruker Acquires AFM and OIM Segments from Veeco II-80
Audax Inks an Agreement with Brown to Acquire Osteobiologic
Nanotechnology II-81
Celgene Acquires Abraxis II-81
ELITech Completes Assets Acquisition of Nanogen II-81
Life Technologies Acquires BioTrove II-82
GSK Inks License With NanoBio to Market NB-001 II-82
CPN Establishes New Medical Nanobiotechnology R&D Center II-82
IBM to Setup New Research Center in Wroclaw II-82
Life Technologies and Zymera Ink Licensing Deal for Quantum
Dots Technology II-83
APR Acquires Nanotechnology Platform Technology for Preparing
Biotechnology Products II-83
Lockheed Teams Up with IIT-Delhi for Nanobiotechnology Research II-83
Piedmont Triad to Institute Statewide Nanobiotech Center II-84
9. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORIC PERSPECTIVE BUILDER II-85Biocon and Abraxis Introduce ABRAXANE in India II-85Starpharma Launches a Research Reagent Kit II-85Monash Enters Into a Deal with National Fabrication Facilityof Australia II-86Taiwan Inks Nanotechnology Collaboration Deal with Australia II-86Avanti Institutes New Targeted Drug Delivery Company, ChikujeeTherapeutics II-86CytoViva Rolls Out New Research Tool for Nanotechnology II-87Dabur Obtains DCGI Approval for Nanoxel in New Indications II-87Researchers Discover New Nanoparticles for Treating BrainInfection II-87Capsulution Tests Nanoparticle-Based Drug Formulation forImproved Bio-Availability II-88Invitrogen Signs Agreement with Genisphere II-88Sigma-Aldrich Signs Deal With Nanoco Technologies II-88Unidym Sells First License Option for Patent Portfolio to MDA II-89Unidym Spins Off Carbon Nanotubes Therapeutics Business intoEnsysce Biosciences II-89Nacalai USA and Nano-C Enter into Collaboration Agreement forHPLC Technology II-89Advanced Materials Technology Obtains License for LBL®Technology from Capsulution II-90Nanogen and The Elitech Group Announce Merger II-90NanoViricides Signs MCRADA Agreement with CDC for Rabies II-90Manhattan Scientifics Acquires Metallicum II-91HemCon Medical Technologies Acquires Alltracel Pharmaceuticals II-91CN Probes Inks Agreement With a Leading MEMS Foundry II-91PrimeGen Biotech LLC Enters into Corporate Alliance with Unidym II-92Ondine Acquires Exclusive License from UCL Business II-92Dabur Introduces Nanotechnology Based Anti-Cancer DrugDelivery System - Nanoxel II-92Mitsui Ties Up With NIOSH to Evaluate Safety of Carbon Nanotubes II-93Unidym Merges with Carbon Nanotechnologies II-93
10. FOCUS ON SELECT GLOBAL PLAYERS II-94
Aduro BioTech (USA) II-94
Arrowhead Research Corporation (USA) II-94
Calando Pharmaceuticals, Inc. (USA) II-94
Agilent Technologies Inc (USA) II-95
Asklepios BioPharmaceutical Inc (USA) II-95
Biosante Phosphate Pharmaceuticals, Inc. (USA) II-95
Celgene Corporation (USA) II-95
Elan Pharmaceuticals, Inc. (USA) II-96
Elitech Group (France) II-96
Flamel Technologies, Inc. (France) II-96
Gilead Sciences Inc (USA) II-97
Life Technologies Corporation (USA) II-97
NanoBio Corporation (USA) II-97
Nanophase Technologies Corporation (USA) II-98
pSivida Ltd (Australia) II-98
Sigma Aldrich Company (USA) II-98
Starpharma Holdings Ltd. (Australia) II-99
Dendritic Nanotechnologies, Inc. (USA) II-99
SkyePharma Pharmaceuticals (UK) II-100
Unidym, Inc. (USA) II-100
Zyvex Instruments LLC (USA) II-100
11. GLOBAL MARKET PERSPECTIVE II-102Table 13: World Recent Past, Current & Future Analysis forNanobiotechnology by Geographic Region - US, Japan, Europe,and Rest of World Markets Independently Analyzed with AnnualRevenue Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart) II-102
Table 14: World Historic Review for Nanobiotechnology by
Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-103
Table 15: World 15-Year Perspective for Nanobiotechnology byGeographic Region - Percentage Breakdown of Revenues for US,Japan, Europe, and Rest of World Markets for Years 2003, 2011& 2017 (includes corresponding Graph/Chart) II-104Analytics by Product Segment II-105Table 16: World Recent Past, Current & Future Analysis forNanomaterials by Geographic Region - US, Japan, Europe, andRest of World Markets Independently Analyzed with AnnualRevenue Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart) II-105
Table 17: World Historic Review for Nanomaterials by
Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-106
Table 18: World 15-Year Perspective for Nanomaterials byGeographic Region - Percentage Breakdown of Revenues for US,Japan, Europe, and Rest of World Markets for Years 2003, 2011& 2017 (includes corresponding Graph/Chart) II-107
Table 19: World Recent Past, Current & Future Analysis for
Solid Inorganic Nanoparticles by Geographic Region - US,
Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for Years
2009 through 2017 (includes corresponding Graph/Chart) II-108
Table 20: World Historic Review for Solid InorganicNanoparticles by Geographic Region - US, Japan, Europe, andRest of World Markets Independently Analyzed with AnnualRevenue Figures in US$ Million for Years 2003 through 2008(includes corresponding Graph/Chart) II-109
Table 21: World 15-Year Perspective for Solid Inorganic
Nanoparticles by Geographic Region - Percentage Breakdown of
Revenues for US, Japan, Europe, and Rest of World Markets for
Years 2003, 2011 & 2017 (includes corresponding Graph/Chart) II-110
Table 22: World Recent Past, Current & Future Analysis forNanocomposites by Geographic Region - US, Japan, Europe, andRest of World Markets Independently Analyzed with AnnualRevenue Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart) II-111
Table 23: World Historic Review for Nanocomposites by
Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-112
Table 24: World 15-Year Perspective for Nanocomposites byGeographic Region - Percentage Breakdown of Revenues for US,Japan, Europe, and Rest of World Markets for Years 2003, 2011& 2017 (includes corresponding Graph/Chart) II-113
Table 25: World Recent Past, Current & Future Analysis for
Nanostructured Materials & Membranes by Geographic Region -
US, Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Revenue Figures in US$ Million for Years
2009 through 2017 (includes corresponding Graph/Chart) II-114
Table 26: World Historic Review for Nanostructured Materials &Membranes by Geographic Region - US, Japan, Europe, and Restof World Markets Independently Analyzed with Annual RevenueFigures in US$ Million for Years 2003 through 2008 (includescorresponding Graph/Chart) II-115
Table 27: World 15-Year Perspective for Nanostructured
Materials & Membranes by Geographic Region - Percentage
Breakdown of Revenues for US, Japan, Europe, and Rest of World
Markets for Years 2003, 2011 & 2017 (includes corresponding
Graph/Chart) II-116
Table 28: World Recent Past, Current & Future Analysis forNanotubes and Fullerenes by Geographic Region - US, Japan,Europe, and Rest of World Markets Independently Analyzed withAnnual Revenue Figures in US$ Million for Years 2009 through2017 (includes corresponding Graph/Chart) II-117
Table 29: World Historic Review for Nanotubes and Fullerenes
by Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-118
Table 30: World 15-Year Perspective for Nanotubes andFullerenes by Geographic Region - Percentage Breakdown ofRevenues for US, Japan, Europe, and Rest of World Markets forYears 2003, 2011 & 2017 (includes corresponding Graph/Chart) II-119
Table 31: World Recent Past, Current & Future Analysis for
Other Nanomaterials by Geographic Region - US, Japan, Europe,
and Rest of World Markets Independently Analyzed with Annual
Revenue Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) II-120
Table 32: World Historic Review for Other Nanomaterials byGeographic Region - US, Japan, Europe, and Rest of WorldMarkets Independently Analyzed with Annual Revenue Figures inUS$ Million for Years 2003 through 2008 (includescorresponding Graph/Chart) II-121
Table 33: World 15-Year Perspective for Other Nanomaterials by
Geographic Region - Percentage Breakdown of Revenues for US,
Japan, Europe, and Rest of World Markets for Years 2003, 2011
& 2017 (includes corresponding Graph/Chart) II-122
Table 34: World Recent Past, Current & Future Analysis forNanodevices/Tools by Geographic Region - US, Japan, Europe,and Rest of World Markets Independently Analyzed with AnnualRevenue Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart) II-123
Table 35: World Historic Review for Nanodevices/Tools by
Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Revenue Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-124
Table 36: World 15-Year Perspective for Nanodevices/Tools byGeographic Region - Percentage Breakdown of Revenues for US,Japan, Europe, and Rest of World Markets for Years 2003, 2011& 2017 (includes corresponding Graph/Chart) II-125Analytics by Application II-126Table 37: World Recent Past, Current & Future Analysis forNanobiotechnology by Application - Pharmaceuticals, MedicalDevices, Medical Research and Others Independently Analyzedwith Annual Revenue Figures in US$ Million for Years 2008through 2017 (includes corresponding Graph/Chart) II-126
Table 38: World 10-Year Perspective for Nanobiotechnology by
Application - Percentage Breakdown of Revenues for
Pharmaceuticals, Medical Devices, Medical Research and Others
for Years 2008, 2011 & 2017 (includes corresponding
Graph/Chart) II-127
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Industry Overview III-1
Public Sector Funding III-1
Major Nanobiotechnology Institutions and Centers III-2
The Nanobiotechnology Center (NBTC) III-2
Key technological advances achieved by NBTC in recent years - III-2
Principal NBTC Partners III-2
Centre for Biologic Nanotechnology (CBN) III-3
Centre for Biological and Environmental Nanotechnology (CBEN) III-3
Regulatory Environment III-3
B.Market Analytics III-5
Table 39: US Recent Past, Current & Future Analysis for
Nanobiotechnology by Technology Segment - Nanomaterials
(Solid Inorganic Nanoparticles, Nanocomposites,
Nanostructured Materials & Membranes, Nanotubes and
Fullerenes, Other Nanomaterials) and Nanodevices/Tools
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-5
Table 40: US Historic Review for Nanobiotechnology byTechnology Segment - Nanomaterials (Solid InorganicNanoparticles, Nanocomposites, Nanostructured Materials &Membranes, Nanotubes and Fullerenes, Other Nanomaterials)and Nanodevices/Tools Markets Independently Analyzed withAnnual Revenue Figures in US$ Million for Years 2003 through2008 (includes corresponding Graph/Chart) III-6
Table 41: US 15-Year Perspective for Nanobiotechnology by
Technology Segment -Percentage Breakdown of Revenues for
Nanomaterials (Solid Inorganic Nanoparticles,
Nanocomposites, Nanostructured Materials & Membranes,
Nanotubes and Fullerenes, Other Nanomaterials) and
Nanodevices/Tools for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) III-7
2. JAPAN III-8A.Market Analysis III-8Public Sector Funding III-8B.Market Analytics III-9Table 42: Japanese Recent Past, Current & Future Analysisfor Nanobiotechnology by Technology Segment - Nanomaterials(Solid Inorganic Nanoparticles, Nanocomposites,Nanostructured Materials & Membranes, Nanotubes andFullerenes, Other Nanomaterials) and Nanodevices/ToolsMarkets Independently Analyzed with Annual Revenue Figuresin US$ Million for Years 2009 through 2017 (includescorresponding Graph/Chart) III-9
Table 43: Japanese Historic Review for Nanobiotechnology by
Technology Segment - Nanomaterials (Solid Inorganic
Nanoparticles, Nanocomposites, Nanostructured Materials &
Membranes, Nanotubes and Fullerenes, Other Nanomaterials)
and Nanodevices/Tools Markets Independently Analyzed with
Annual Revenue Figures in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) III-10
Table 44: Japanese 15-Year Perspective for Nanobiotechnologyby Technology Segment - Percentage Breakdown of Revenues forNanomaterials (Solid Inorganic Nanoparticles,Nanocomposites, Nanostructured Materials & Membranes,Nanotubes and Fullerenes, Other Nanomaterials) andNanodevices/Tools for Years 2003, 2011 & 2017 (includescorresponding Graph/Chart) III-11
3. EUROPE III-12
A.Market Analysis III-12
Market Overview III-12
European Union Banks Heavily on Nanobiotechnology III-12
Nano2Life Network III-13
Major Nanobiotechnology Networks in Europe as of the Year
2006 III-14
Public Sector Funding III-14
Regulatory Environment III-14
Registration for Novel Nanobiotech Drugs Pose Major Bottlenecks III-15
Focus on Select Markets III-15
Germany III-15
France III-15
United Kingdom III-16
Russia III-16
Russian Biotech Players Eye Partnerships with Indian
Counterparts III-17
Rest of Europe III-18
Ireland III-18
Market Overview III-18
Key Research Institutions/Centers in Nanobiotechnology III-18
The Tyndall National Institute III-18
The Centre for Research on Adaptive Nanostructures and
NanoDevices III-19
The National Centre for Sensor Research III-19
The Sami Nasr Institute for Advanced Materials Science III-19
B.Market Analytics III-20
Table 45: European Recent Past, Current & Future Analysis
for Nanobiotechnology by Technology Segment - Nanomaterials
(Solid Inorganic Nanoparticles, Nanocomposites,
Nanostructured Materials & Membranes, Nanotubes and
Fullerenes, Other Nanomaterials) and Nanodevices/Tools
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-20
Table 46: European Historic Review for Nanobiotechnology byTechnology Segment - Nanomaterials (Solid InorganicNanoparticles, Nanocomposites, Nanostructured Materials &Membranes, Nanotubes and Fullerenes, Other Nanomaterials)and Nanodevices/Tools Markets Independently Analyzed withAnnual Revenue Figures in US$ Million for Years 2003 through2008 (includes corresponding Graph/Chart) III-21
Table 47: European 15-Year Perspective for Nanobiotechnology
by Technology Segment - Percentage Breakdown of Revenues for
Nanomaterials (Solid Inorganic Nanoparticles,
Nanocomposites, Nanostructured Materials & Membranes,
Nanotubes and Fullerenes, Other Nanomaterials) and
Nanodevices/Tools for Years 2003 2011 & 2017 (includes
corresponding Graph/Chart) III-22
4. REST OF WORLD III-23A.Market Analysis III-23Public Sector Funding III-23Focus on Select Markets III-23Australia III-23Market Overview III-23Major Institutions III-24Commonwealth Scientific and Industrial ResearchOrganisation (CSIRO) III-24India III-24Market Overview III-24Government Takes Big Initiatives to PromoteNanobiotechnology III-24Agriculture, Livestock Sectors to Warm Up toNanobiotechnology Benefits III-25Korea III-25Taiwan III-26Nanotechnology in Medicine - Small Yet Growing Segment inTaiwan III-27Iran III-27B.Market Analytics III-28Table 48: Rest of World Recent Past, Current & FutureAnalysis for Nanobiotechnology by Technology Segment -Nanomaterials (Solid Inorganic Nanoparticles,Nanocomposites, Nanostructured Materials & Membranes,Nanotubes and Fullerenes, Other Nanomaterials) andNanodevices/Tools Markets Independently Analyzed with AnnualRevenue Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart) III-28
Table 49: Rest of World Historic Review for
Nanobiotechnology by Technology Segment - Nanomaterials
(Solid Inorganic Nanoparticles, Nanocomposites,
Nanostructured Materials & Membranes, Nanotubes and
Fullerenes, Other Nanomaterials) and Nanodevices/Tools
Markets Independently Analyzed with Annual Revenue Figures
in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) III-29
Table 50: Rest of World 15-Year Perspective forNanobiotechnology by Technology Segment - PercentageBreakdown of Revenues for Nanomaterials (Solid InorganicNanoparticles, Nanocomposites, Nanostructured Materials &Membranes, Nanotubes and Fullerenes, Other Nanomaterials)and Nanodevices/Tools for Years 2003, 2011 & 2017 (includescorresponding Graph/Chart) III-30IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 117 (including Divisions/Subsidiaries - 122)
------------------------------------------Region/Country Players------------------------------------------The United States 75Canada 2Japan 1Europe 32France 3Germany 8The United Kingdom 9Rest of Europe 12Asia-Pacific (Excluding Japan) 9Middle-East 3------------------------------------------
To order this report:Nanotechnology Industry: Global Nanobiotechnology IndustryCheck our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article